by Joanne Hedin | Nov 15, 2024 | Uncategorized
FCTDI is pleased to announce that it has been awarded a Phase I Contract SBIR from NIAID/NIH entitled “Combinations of Oral Antibiotics to Treat Syphilis”....
by Joanne Hedin | Nov 11, 2024 | Uncategorized
Allen Reitz, CEO of FCTDI, has been awarded the 2nd Annual Timothy E. Block Biotech Impact Award...
by Joanne Hedin | Aug 2, 2024 | Uncategorized
Fox Chase Therapeutics Discovery, Inc. (formerly known as Fox Chase Chemical Diversity Center) Announces That It Has Been Awarded a Phase II STTR grant from the National Institutes of Health (NIAID) with Prof. Robert Ricciardi of the University of Pennsylvania...
